Home › NDC Lookup › RxCUI directory › RxCUI 2471878

Betamethasone dipropionate 0.64 MG/ML / calcipotriene 0.05 MG/ML Topical Cream [Wynzora] — RxCUI 2471878

RxNorm drug concept · Semantic branded drug
RxCUI 2471878 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2471878
Official nameBetamethasone dipropionate 0.64 MG/ML / calcipotriene 0.05 MG/ML Topical Cream [Wynzora]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asWynzora (calcipotriene 0.005 % / betamethasone dipropionate 0.064 % ) Topical Cream; Wynzora 0.005 % / 0.064 % Topical Cream
FDA products mapped1
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Calcipotriene Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats plaque psoriasis. The foam is for the scalp and body in adults and children 4 and older. Pellix is a scalp solution.
  • Comb your hair to remove scales and part it. Apply it twice daily only to the lesions and rub it in gently. Keep it off your forehead and away from your eyes, and wash your hands a...
  • How do I apply the Pellix scalp solution?
  • Mild redness, pain or itching where you apply it are the most common. Call me or your doctor if irritation gets excessive or you have a sensitivity reaction.
📖 Read our full Calcipotriene Topical guide →

🕸️ Concept Web — How Betamethasone dipropionate 0.64 MG/ML / calcipot... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Betamethasone dipropionate 0.64 MG/ML / calcipotriene 0.05 MG/ML Topical Cream [Wynzora] RxCUI 2471878

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Betamethasone 1514
    • Calcipotriene 29365
    • Betamethasone / calcipotriene 690419
    • Betamethasone dipropionate 19254
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Wynzora 2471874
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Betamethasone / calcipotriene Topical Cream 2471872
    • Betamethasone dipropionate / calcipotriene Topical Cream 2646228
    • Betamethasone / calcipotriene Topical Product 1153789
    • Betamethasone dipropionate / calcipotriene Topical Product 2660029
    • Betamethasone / calcipotriene Topical Cream [Wynzora] 2471876
    • Betamethasone dipropionate / calcipotriene Topical Cream [Wynzora] 2654822
    • Wynzora Topical Product 2471877
    • Topical Cream 316982
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Betamethasone dipropionate 0.64 MG/ML / calcipotriene 0.05 MG/ML Topical Cream SCD · 2471873
  • Betamethasone dipropionate 0.64 MG/ML SCDC · 2471871
  • Calcipotriene 0.05 MG/ML SCDC · 340092
  • Betamethasone / calcipotriene Topical Cream SCDF · 2471872
  • Betamethasone dipropionate / calcipotriene Topical Cream SCDFP · 2646228
  • Betamethasone / calcipotriene Topical Product SCDG · 1153789
  • Betamethasone dipropionate / calcipotriene Topical Product SCDGP · 2660029

Brand-Name Concepts

  • Betamethasone dipropionate 0.64 MG/ML / calcipotriene 0.05 MG/ML [Wynzora] SBDC · 2471875
  • Betamethasone / calcipotriene Topical Cream [Wynzora] SBDF · 2471876
  • Betamethasone dipropionate / calcipotriene Topical Cream [Wynzora] SBDFP · 2654822
  • Wynzora Topical Product SBDG · 2471877
  • Wynzora BN · 2471874

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2471878 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
73499-0001-01 1 TUBE in 1 CARTON (73499-001-01) / 60 g in 1 TUBE Wynzora MC2 Therapeutics Ltd 2021-06-30
73499-0001-03 10 TUBE in 1 CARTON (73499-001-03) / 5 g in 1 TUBE Wynzora MC2 Therapeutics Ltd 2021-06-30
Observed labelers: MC2 Therapeutics Ltd (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.